Your browser is no longer supported. Please, upgrade your browser.
Protalix BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-0.39 Insider Own22.48% Shs Outstand45.38M Perf Week-0.63%
Market Cap71.25M Forward P/E39.25 EPS next Y0.04 Insider Trans-8.26% Shs Float34.67M Perf Month-15.59%
Income- PEG- EPS next Q-0.08 Inst Own20.94% Short Float6.02% Perf Quarter-74.76%
Sales52.57M P/S1.36 EPS this Y-95.50% Inst Trans- Short Ratio0.91 Perf Half Y-65.72%
Book/sh0.32 P/B4.91 EPS next Y109.30% ROA- Target Price- Perf Year-57.57%
Cash/sh- P/C- EPS next 5Y25.00% ROE- 52W Range1.46 - 7.02 Perf YTD-56.75%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-77.64% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low7.53% ATR0.11
Employees207 Current Ratio- Sales Q/Q-47.70% Oper. Margin- RSI (14)33.44 Volatility8.81% 6.40%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.33 Prev Close1.67
ShortableYes LT Debt/Eq- EarningsMay 14 BMO Payout- Avg Volume2.30M Price1.57
Recom2.00 SMA20-10.16% SMA50-27.94% SMA200-57.80% Volume752,448 Change-5.99%
Jun-08-20Reiterated H.C. Wainwright Buy $3 → $11
Apr-17-17Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16Initiated Rodman & Renshaw Buy $3.50
Apr-23-15Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14Initiated R. F. Lafferty Buy $8
May-02-12Reiterated Oppenheimer Outperform $9 → $11
May-02-12Downgrade Canaccord Genuity Buy → Hold $8 → $8
Apr-30-12Downgrade Auriga Buy → Hold $8 → $8
Oct-13-11Initiated Morgan Joseph Hold
Mar-17-11Downgrade WBB Securities Strong Buy → Buy $10
Nov-09-10Reiterated Oppenheimer Outperform $10 → $12
Oct-14-10Reiterated UBS Buy $9 → $10.75
Dec-02-09Reiterated Hapoalim Outperform $10 → $12
Sep-22-09Initiated Canaccord Adams Buy
Sep-02-09Initiated Hapoalim Outperform $10
Dec-01-08Reiterated Oppenheimer Outperform $6 → $4
Mar-11-08Initiated UBS Buy $6
Nov-20-07Initiated CIBC Wrld Mkts Sector Outperform $7
Jun-30-21 09:56AM  
Jun-28-21 06:50AM  
Jun-07-21 10:18PM  
Jun-05-21 08:16PM  
Jun-03-21 09:28AM  
Jun-02-21 12:10PM  
May-25-21 06:50AM  
May-14-21 06:50AM  
May-07-21 10:30AM  
Apr-29-21 05:45AM  
Apr-28-21 03:25PM  
Apr-07-21 05:15AM  
Mar-30-21 06:50AM  
Mar-22-21 06:50AM  
Mar-04-21 06:50AM  
Feb-24-21 08:03AM  
Feb-23-21 08:04AM  
Feb-22-21 03:20AM  
Feb-18-21 08:02AM  
Feb-12-21 05:54AM  
Feb-11-21 09:16PM  
Feb-10-21 07:01AM  
Feb-01-21 06:50AM  
Jan-04-21 06:50AM  
Dec-30-20 06:50AM  
Dec-21-20 06:40AM  
Dec-15-20 07:15AM  
Nov-30-20 03:38PM  
Nov-27-20 06:50AM  
Nov-05-20 06:50AM  
Oct-29-20 01:33PM  
Oct-26-20 06:50AM  
Oct-22-20 06:50AM  
Oct-20-20 12:13PM  
Oct-02-20 08:00AM  
Sep-08-20 06:55AM  
Aug-24-20 06:50AM  
Aug-20-20 03:44PM  
Aug-11-20 06:50AM  
Aug-10-20 06:50AM  
Aug-06-20 01:02PM  
Aug-03-20 09:13AM  
Jul-23-20 02:29PM  
Jul-22-20 07:28PM  
Jun-18-20 12:20PM  
Jun-08-20 05:00PM  
Jun-03-20 08:46PM  
Jun-01-20 06:50AM  
May-29-20 09:43AM  
May-28-20 06:50AM  
May-22-20 04:05PM  
May-11-20 06:50AM  
Mar-18-20 12:12PM  
Mar-16-20 06:50AM  
Mar-12-20 08:04AM  
Mar-05-20 07:00AM  
Feb-11-20 10:52AM  
Feb-10-20 04:05PM  
Feb-06-20 06:50AM  
Feb-04-20 09:00AM  
Jan-30-20 07:30AM  
Jan-14-20 05:09PM  
Dec-19-19 06:50AM  
Dec-09-19 04:05PM  
Nov-29-19 10:37PM  
Nov-27-19 06:50AM  
Nov-19-19 09:26AM  
Nov-18-19 06:50AM  
Nov-13-19 11:59AM  
Nov-07-19 09:25AM  
Oct-31-19 10:34AM  
Oct-29-19 07:00AM  
Oct-17-19 07:40AM  
Sep-25-19 06:22PM  
Sep-24-19 07:00AM  
Sep-02-19 11:40AM  
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundacao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is headquartered in Karmiel, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dexcel Pharma Technologies Ltd10% OwnerJun 03Sale2.25857,5061,932,3043,637,314Jun 03 05:40 PM
Dexcel Pharma Technologies Ltd10% OwnerJun 02Sale2.5661,211156,5534,494,820Jun 03 05:40 PM